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Purpose: Integrating genomic sequencing in clinical care requires
standardization of variant interpretation practices. The Clinical Genome
Resource has established expert panels to adapt the American College of
Medical Genetics and Genomics/Association for Molecular Pathology
classification framework for specific genes and diseases. The Cardiomyo-
pathy Expert Panel selectedMYH7, a key contributor to inherited cardio-
myopathies, as a pilot gene to develop a broadly applicable approach.
Methods: Expert revisions were tested with 60 variants using a
structured double review by pairs of clinical and diagnostic laboratory
experts. Final consensus rules were established via iterative discussions.
Results: Adjustments represented disease-/gene-informed specifica-
tions (12) or strength adjustments of existing rules (5). Nine rules were
deemed not applicable. Key specifications included quantitative
frameworks for minor allele frequency thresholds, the use of
segregation data, and a semiquantitative approach to counting
multiple independent variant occurrences where fully controlled
case-control studies are lacking. Initial inter-expert classification
concordance was 93%. Internal data from participating diagnostic
laboratories changed the classification of 20% of the variants (n = 12),
highlighting the critical importance of data sharing.
Conclusion: These adapted rules provide increased specificity for use
in MYH7-associated disorders in combination with expert review and
clinical judgment and serve as a stepping stone for genes and disorders
with similar genetic and clinical characteristics.
Genet Med advance online publication 4 January 2018
Key Words: cardiomyopathy; ClinGen; HCM; myosin heavy
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INTRODUCTION
Determining the clinical significance of sequence variants is a
complex process that involves gathering and assigning relative
weights to a multitude of data gathered from a diverse set of
resources. Variant classification has evolved in a decentralized
fashion leading to a multitude of approaches, most developed
by molecular diagnostic laboratories for internal use.
As sequencing tests become a routine tool in managing
health, it is vital to harmonize and centralize knowledge and
approaches. Key advancements included the creation of the
National Center for Biotechnology Information’s ClinVar
database (http://www.ncbi.nlm.nih.gov/clinvar/), which has
quickly become a valuable centralized resource for clinically
classified variants, and the National Human Genome
Research Institute–funded Clinical Genome Resource
(ClinGen, http://www.clinicalgenome.org), which serves as a
body for managing and centralizing clinically relevant
genomic knowledge. The historic lack of standardization is
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a major contributor for interpretation differences, which have
been revealed by increased data sharing through ClinVar.1–3
Many of these differences represent misclassifications, which
can have serious consequences, especially for medically
actionable variants as illustrated by Gaba et al.,4 who reported
that implantable cardioverter-defibrillators were implanted
based on the incorrect classification of a variant as causative
for long QT syndrome.
The American College of Medical Genetics and Genomics
(ACMG) and the Association for Molecular Pathology (AMP)
have responded to the urgent need for an updated variant
classification framework by releasing a landmark guidance
document,5 which has since been adopted by many US and
international laboratories.6 However, this framework was
designed to have universal applicability, and therefore
requires significant expertise to be applied correctly for
specific diseases and genes.
Lack of clinical domain expert knowledge is emerging as a
key contributor to incorrect classifications.2,7 Besides adding
disease and gene specifications for certain rules (including
flagging rules that are not applicable), there is a critical need
to provide more granularity surrounding frequency thresh-
olds that drive the benign spectrum of rules, to specify
thresholds for assigning increasing weight depending on the
degree of segregation with disease, and to provide guidance
surrounding the use of functional data.7 Some studies have
proposed approaches and solutions;8–11 however, systematic
expert-led efforts are needed to create disease- and/or gene-
specific derivatives of the original ACMG/AMP framework.
ClinGen has emerged as a critical facilitator in this domain
and has established a rich infrastructure including disease-
specific expert working groups that have been charged with
accomplishing this goal.3
Here we report the work of ClinGen’s Inherited Cardio-
myopathy Expert Panel (CMP-EP), which adapted the
ACMG/AMP framework for use in myosin heavy chain 7
(MYH7)-associated cardiomyopathies with the aim of
improving consistency for variant interpretation and expert
curation of reported MYH7 variants for submission to
ClinVar (3 star). These disorders include hypertrophic,
dilated, and restrictive cardiomyopathy (HCM, DCM, and
RCM), which are collectively among the most prevalent
Mendelian conditions and affect 1 in 200–500 individuals.12,13
MYH7 is the second most common inherited cause of HCM
and third most common inherited cause of DCM, primarily
due to missense variants that are dominantly inherited,
although de novo variants have been reported.14,15
MATERIALS AND METHODS
ClinGen’s Inherited Cardiomyopathy Expert Panel
The CMP-EP operates under the umbrella of the Cardiovas-
cular Domain Working Group. Members were selected to
provide a balanced representation of expertise in clinical
cardiology, clinical research, molecular diagnostics, genetic
counseling, and genomic medicine. Additional emphasis was
placed on global representation (United States, United
Kingdom, the Netherlands, and Australia) to lay the
foundation for international harmonization.
Decision-making framework
A subset of the CMP-EP formed a core task team with clinical
as well as molecular diagnostic expertise and representation
from three institutions (M.A.K., Partners HealthCare Labora-
tory for Molecular Medicine; C.C., Stanford University; A.M.,
Ohio State University). This task team reviewed the original
ACMG/AMP framework5 and developed proposed changes to
adapt them for MYH7. Proposed adaptations were discussed
by the CMP-EP using conference calls, e-mail, or electronic
surveys to arrive at consensus decisions (Supplementary Text
S1 online).
Project design
An initial classification exercise included 10 variants and
served as a foundation for subsequent rule adaptations. These
variants were independently scored by members of the core
task team using the original ACMG/AMP framework as well
as their own institutions’ variant interpretation criteria.
Subsequent work was carried out as shown in Figure 1.
Draft rules were applied to 60 MYH7 variants (including the
initial 10), which were selected (i) as a representative
spectrum of variant types for MYH7, (ii) to test as many
rules as possible, (iii) to cover a range of classifications, and
(iv) to include discrepant ClinVar assertions. Evidence for
each variant was compiled by a set of curators (K.O., K.S., M.
T.) and applicable rules were selected. Each variant was then
reviewed by two task team members (one with clinical
expertise and one with laboratory expertise; M.A.K., J.B., C.C.,
A.M.) and conflicts resulting from clerical errors and rule
misuse were corrected. A discussion with the full CMP-EP
was triggered when reviewers did not agree or raised concerns
regarding the “fit” of a rule. Variants representing contro-
versial items were used to drive additional rule adjustments by
the CMP-EP. Adjusted rules were disseminated to the CMP-
EP to allow for a final comment period. Additional guidance
was provided by ClinGen’s Sequence Variant Interpretation
Working Group, which harmonizes framework adaptation
efforts by various clinical domain working groups (https://
www.clinicalgenome.org/working-groups/genomic-variant-
workgroup/sub-groups/sequence-variant-interpretation-wg/).
Variants and the adapted rule framework were submitted to
ClinVar under a 3-star (expert panel–reviewed) status.
Curation data sources and data collection method (publicly
available data)
Variants were curated using the variant assessment
process and data sources described by Duzkale et al.16
(Supplementary Table S1). All databases accessed August
to September 2015; reference transcript: NM_000257.3).
Additional case-level data
The number of independent observations of the 60 pilot
variants, basic phenotype information, and segregation with
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disease was available from several diagnostic or research
cohorts (Partners HealthCare Laboratory for Molecular
Medicine, Invitae, the Sarcomeric Human Cardiomyopathy
Registry (https://theshareregistry.org/), the Australian Genetic
Heart Disease Registry (http://www.heartregistry.org.au/), the
National Institute for Health Research Cardiovascular Bio-
medical Research Unit at Royal Brompton Hospital and
Imperial College London, and the National Heart Centre
Singapore). Consideration was taken to account for cases that
were known or suspected to be part of more than one cohort.
Statistical approaches
Multiple proband rules (PS4, PS4_Moderate,
PS4_Supporting)
The current ACMG/AMP framework assigns weight to
increased prevalence of a variant in cases compared with
controls (PS4), but does not provide guidance for combining
separate studies reporting the same variant. We created
thresholds of proband occurrences that qualify for supporting,
moderate, and strong weight as follows and outlined in more
detail in Supplementary Table S2. This approach represents a
“quasi case-control” analysis. Proband cohort sizes were
modeled based on the cohorts available for this study, focusing
on Caucasian and African American ancestries (reflecting the
main ancestries represented among cohorts available in this
study). The corresponding ExAC cohorts were used as proxies
for healthy controls. Odds ratios and P values were computed for
1–15 probands carrying a variant assuming absence/extreme
rarity in controls (rule PM2 is met) using the two-sided Fisher’s
exact test to evaluate the null hypothesis of conditional
independence. This approach has limitations (for details see
Supplementary Table 2) but provides a practical means for
clinical variant assessment workflows.
Segregation thresholds
Since cardiomyopathies are characterized by variable age at
onset and reduced penetrance, logarithm of odds (LOD)
scores were estimated by counting the number of informative
meioses separating affected variant carriers across all families
with this variant (i.e., without considering unaffected
individuals). Affected noncarriers indicated nonsegregation.
Under these conditions the calculation of LOD score
simplifies to LOD = log10(2
n), where n is the number of
informative meiosis observed.
RESULTS AND DISCUSSION
MYH7 is a major contributor to several cardiomyopathies
(HCM, DCM, RCM). Due to their high combined prevalence
and severe health outcomes, MYH7 is one of the most
frequently tested genes in a clinical setting. As a first step
toward modifying the ACMG/AMP framework, the CMP-EP
conducted a preliminary exercise comparing inter-expert
concordance for 10 representative MYH7 variants classified
using the ACMG/AMP framework alongside the experts’
respective institutional criteria. As in similar previously
reported studies,7 this revealed low inter-expert concordance
(20%) for the ACMG/AMP framework compared with high
concordance (90%) when institutional criteria were used (data
not shown). The subsequent adaptation of the ACMG/AMP
framework for MYH7 was carried out as shown in Figure 1.
Summary of specifications
Two characteristics of the ACMG/AMP framework had a major
influence on the specifications made. Due to its design to have
general applicability across all Mendelian disorders, some rules
are overly conservative in the setting of a specific disorder. This
is best illustrated by BA1, the allele frequency threshold above
which a variant is considered benign. For many Mendelian
conditions, the default threshold of 5% is orders of magnitude
higher than it needs to be. In addition, the framework contains
several areas of vagueness (such as the absence of quantitative
guidance for increasing the weight depending on the extent of
“segregation with disease”). Table 1 provides a summary of the
adapted ACMG/AMP framework for use in MYH7-associated
cardiomyopathies. Of the original 28 ACMG/AMP rules, 9 were
deemed not applicable and another 12 required disease- and/or
gene-specific adjustments. Five rules were given modified
strength criteria. A full description of rules with additional
detail is provided in Supplementary Text S2. The following
sections highlight approaches and key specifications.
Disease- and gene-specific adaptations
Minor allele frequency–driven rules (BA1, BS1, and PM2)
The CMP-EP modified BA1 using extremely conservative
values for disease prevalence, gene contribution, and estimated
Phase 1
General ACMG/AMP framework review (Core Task Team)
Development of draft modifications (CMP-EP)
Phase 2
Data entry and evaluation of 60 variants (Curators)
Double review -1 clinical & 1 laboratory (Core Task Team)
Concordance analysis (Core Task Team & CMP-EP)
Data clean-up & error removal (Core Task Team)
Phase 3
Final adjustments (CMP-EP)
Final
3-star expert panel ClinVar submission (CMP-EP)
Project Phases
Figure 1 Summary of ClinGen Inherited Cardiomyopathy Expert
Panel (CMP-EP) involvement. Phase 1: Disease/gene and other
specifications made to established American College of Medical Genetics
and Genomics/Association for Molecular Pathology (ACMG/AMP)
framework. Phase 2: Selection and review of 60 pilot variants by two
independent reviewers. Classifications were then compared and discussed
to resolve any conflicts. Phase 3: Additional adjustments to variant
classifications. Final: Expert panel variant classifications submitted to
ClinVar for public accessibility. Expert panel ratings in ClinVar are
denoted with a three-star rating.
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Table 1 Summary of the adapted ACMG/AMP pathogenic and benign criteria
Pathogenic criteria
Rule Specification
type
Rule description
VS PVS1 Removed Null variant in gene with established LOF as disease mechanism
Strong PS1 No change Different nucleotide change (same amino acid) as a previously established pathogenic variant
PS2 Disease/gene De novo (paternity confirmed) in a patient with disease and no family history
PS3 Disease/gene Functional studies of mammalian knock-in models supportive of a damaging effect on the gene or gene product
PS4 Disease/gene Prevalence of the variant in affected individuals is significantly increased compared with the prevalence in
controls - OR - Variant identified in ≥ 15 probands with consistent phenotypes
PP1_Strong Modif.
strength
Variant segregates with ≥ 7 meioses
Moderate PM1 Disease/gene Hotspot/est. functional domain (amino acids 181–937) without benign variation
PM2 Disease/gene Absent/extremely rare (o0.004%) from large population studies
PM3 Removed Detected in trans with a pathogenic variant (recessive)
PM4 No change Protein length changes due to in-frame deletions/insertions of any size in a nonrepeat region or
stop-loss variants
PM5 No change Missense change at an amino acid residue where a different missense change previously established
as pathogenic
PM6 Disease/gene Confirmed de novo without confirmation of paternity
PVS1_Moderate Modif.
strength
Null variant in gene with evidence supporting LOF as disease mechanism
PS4_Moderate Modif.
strength
Variant identified in ≥6 probands with consistent phenotypes
PP1_Moderate Modif.
strength
Variant segregates in ≥ 5 meioses
Supporting PP1 Disease/gene Variant segregates in ≥ 3 meioses
PP2 Removed Missense variant in a gene that has a low rate of benign missense variation and where missense
variants are a common mechanism of disease
PP3 No change Multiple lines of computational evidence support a deleterious effect on the gene or gene product
PP4 Removed Phenotype specific for disease with single genetic etiology
PP5 Removed Reputable source reports as pathogenic
PS4_Supporting Modif.
strength
Variant identified in ≥2 probands with consistent phenotypes
Benign criteria
Rule Specification
type
Rule description
SA BA1 Disease/gene Allele frequency is ≥ 0.1% based on the filtering allele frequency in ExAC
Strong BS1 Disease/gene Allele frequency is ≥ 0.02% based on the filtering allele frequency in ExAC provided there is no
conflicting information
BS2 Removed Observed in healthy adult with full penetrance expected at an early age
BS3 No change Functional studies of mammalian knock-in models supportive of no damaging effect on protein
function or splicing
BS4 Disease/gene Nonsegregation in affected members of a family
Supporting BP1 Removed Missense variant in gene where only LOF causes disease
BP2 Disease/gene Observed as comp het (in trans) or double het in genes with overlapping function (e.g., sarcomere genes)
without increased disease severity or observed in cis with a pathogenic variant in any inheritance pattern
BP3 Removed In-frame deletions/insertions in a repetitive region without a known function
BP4 No change Multiple lines of computational evidence suggest no impact on gene or gene product
BP5 Disease/gene Variant found in a case with an alternate molecular basis for disease
BP6 Removed Reputable source reports as benign
BP7 No change A silent variant for which splicing prediction algorithms predict no impact to the splice consensus sequence
nor the creation of a new splice site -AND- the nucleotide is not highly conserved
ACMG/AMP, American College of Medical Genetics and Genomics/Association for Molecular Pathology; LOF, loss of function; Modif. strength, modified rule strength;
Removed, not applicable to MYH7-associated disease; SA, standalone; VS, very strong.
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penetrance of MYH7 variants (Figure 2, for additional detail
see Supplementary Text S3). Across MYH7-associated
diseases, prevalence values were compiled from the literature
and the most conservative one was selected to derive a
threshold that is applicable to all (1/200). Penetrance was set
deliberately low at 30%. To control for uncertainty in estimated
minor allele frequencies of very rare variants in smaller cohorts,
a statistical correction (95% Poisson distribution) was added.11
This correction (termed “filtering allele frequency”) is now
available for each variant for all ExAC cohorts, (http://exac.
broadinstitute.org/). The final BA1 threshold was set at 0.1%.
A variant that is observed at this minor allele frequency in the
general population could theoretically be pathogenic under the
assumption that it is the only pathogenic variant. Because of
the extremely conservative approach, this threshold is likely two
orders of magnitude higher than the true threshold and can be
used safely in a diagnostic setting.
The threshold for BS1 (allele frequency too high for
disorder) was derived using the same approach except that
allelic heterogeneity was now considered (i.e., gene contribu-
tion was replaced by the maximum credible variant
contribution, which encompasses both gene and variant
contribution, Figure 2). This gives rise to a more aggressive
threshold with less room for error, which is acceptable given
the less definitive classification. The prevalence of the most
common pathogenic cardiomyopathy variant was used to
define the maximum theoretical population frequency for a
pathogenic allele (Whiffin et al.11 and Supplementary Text
S3). The final BS1 threshold was set at a filtering allele
frequency of ≥ 0.02%. A variant observed at this minor allele
frequency can be assumed to be likely benign provided that
there is no substantial contradictory evidence supporting
pathogenicity. Allowing a variant to reach a likely benign
classification based on BS1 alone represents a revision of the
original ACMG/AMP framework by ClinGen’s Sequence
Variant Interpretation Working Group.17 The CMP-EP
added the following safeguard to BS1: Because our current
knowledge of the genetic architecture of HCM is largely
derived from predominantly Caucasian proband cohorts, the
threshold should only be applied to populations where
sufficient numbers of probands have been deeply analyzed,
leaving the possibility open that more common pathogenic
variants may exist in less well-characterized populations. Both
BA1 and BS1 were tested in a large diagnostic cohort
(Partners HealthCare Laboratory for Molecular Medicine)
and no currently known likely pathogenic or pathogenic
MYH7 variant would be misclassified as likely benign or
benign (data not shown).
The CMP-EP recommends activating rule PM2 (absent in
population databases) when the filtering allele frequency is
o0.004%. The PM2 threshold used more realistic prevalence
and penetrance values (1/500, 50%), which typically repre-
sents a very small/negligible number of alleles in the ExAC
database.
Segregation with disease (PP1, PP1_Moderate, PP1_Strong)
The ACMG/AMP framework assigns supporting evidence to
cosegregation (PP1) and states that higher weight can be
assigned with an increasing degree of segregation, but does
not define thresholds. The CMP-EP specified three levels of
evidence using autosomal dominant likelihood ratios of 10 (3
meioses, LOD 0.9), 30 (5 meioses, LOD 1.5), and 100 (7
meioses, LOD 2.1) to count as supporting, moderate, and
strong evidence provided that PM2 (absent or rare in large
population cohorts) is met. Finally, the CMP-EP waived the
ACMG/AMP recommendation for demonstrating segregation
in more than one family given that MYH7 is a well-
established cardiomyopathy gene.
Increased prevalence of variant in probands versus controls
(PS4, PS4_Moderate, PS4_Supporting)
Rule PS4 is designed for variants that are significantly
enriched in probands. While traditional case-control studies
using phenotyped case and control cohorts are typically not
available for rare, Mendelian variants, it is not uncommon
that multiple separate studies report the same variant in
cohorts of modest size. To be able to utilize combined
proband counts across different studies, the CMP-EP created
a framework using the ExAC cohort as a proxy for healthy
controls. As with segregation, evidence levels were assigned
based on likelihood ratios with ideal target thresholds being
10 (supporting), 30 (moderate), and 100 (strong). To simplify
use in current molecular diagnostic practice, where statistical
tools are typically not embedded in routine workflows,
conservative universal thresholds were set to proband counts
of ≥ 2 (supporting), ≥ 6 (moderate), and ≥ 15 (strong).
Moderate (but acceptable) deviations from the targeted odds
ratios (ORs) for the two main racial cohorts used (NFE, non-
Finnish European; AFR, African American) were deemed
acceptable in return for ease of use (supporting: OR [AFR|
NFE] = [10.4|13.4], moderate: OR [AFR|NFE] = [31.3|40.1],
and strong: OR [AFR|NFE] = [79.1|100]). To apply these
rules, rule PM2 must be met. These proband counts are
extremely conservative to balance the limitations of the
BA1
                           
[disease prevalence] x [% gene contribution]
[penetrance]
                           
[disease prevalence] x [% max path. variant ]
[penetrance]
BS1
≥ 0.1%*
≥ 0.02%*
* = after statistical correction (95% Poisson)
Figure 2 Derivation of allele frequency thresholds for rules BA1
and BS1. Disease prevalence = 1/200 individuals (1/400 chromosomes).
Penetrance = 30%. % gene contribution = 10.6%. % maximum
pathogenic variant contribution (max path. variant) = 2%.
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underlying statistical approach and the risk of double-
counting probands that is inherent when working with
published data.
De novo occurrence
Rule PS2 (de novo in a patient with the disease and no family
history, paternity and maternity confirmed): The CMP-EP
removed the requirement to prove maternity because the
likelihood of undisclosed nonmaternity (e.g., due to surro-
gacy) was considered rare. In addition, the following
specifications were added: (i) “no family history” is defined
as the absence of diagnosed disease or suspicious findings in a
three-generation pedigree and (ii) both parents must be
genotype and phenotype negative after a thorough clinical
evaluation that ideally includes a combination of electro-
cardiogram and echo or cardiac magnetic resonance imaging
for maximum sensitivity (Supplementary Text S2). When
paternity has not been established, de novo occurrence
receives moderate weight (PM6) but the CMP-EP allowed
upgrading to “strong” (PS2) when at least three de novo
occurrences have been documented.
Dealing with ambiguous phenotypes when counting
multiple or segregation with disease
Left ventricular noncompaction: It is currently debated
whether left ventricular noncompaction is a distinct cardio-
myopathy, a morphological trait shared by different cardio-
myopathies, or an entirely benign structural variant.18–20 The
CMP-EP therefore recommended that individuals with
isolated left ventricular noncompaction (no additional
cardiomyopathy such as HCM or DCM present) should not
be added to proband or segregation counts in the context of
HCM and DCM. End-stage HCM: Due to the challenge in
distinguishing between end-stage HCM and DCM, a
conservative approach was taken to not include DCM cases
in proband or segregation counts for HCM variants, unless
earlier clinical evidence supported the HCM phenotype.
Functional data
The ACMG/AMP framework assigns strong weight to well-
established in vitro or in vivo functional studies that are
supportive of a damaging effect on the gene or protein (PS3).
The normal function of the protein encoded by MYH7 is to
convert energy from adenosine triphosphate hydrolysis into
mechanical force to allow for muscle contractility.21 After
reviewing the assays used to measure this function for the 60
pilot variants, the CMP-EP determined that “strong func-
tional evidence” can only be provided by a mammalian
variant-specific knock-in model (Supplementary Table S3).
Other in vivo models that alter dosage of the normal protein
(transgenic or knockout mice, zebrafish knock-downs) are not
acceptable as they do not provide clues about the importance
of a particular variant. Typically performed MYH7 in vitro
assays were generally deemed to have relatively low positive
predictive value (either due to low accuracy or low correlation
between an observed effect and the ability to cause disease)
and are therefore currently not considered strong evidence.
However, the CMP-EP recognized that in the event that
in vitro models that accurately predict the effect in vivo
become available, their weight can be reconsidered.
Incorporating protein domain information
The ACMG/AMP framework assigns supporting evidence of
pathogenicity to missense variants in a gene that has a low rate
of missense variation, provided that missense variants are a
common mechanism of disease (PP2) and moderate evidence
for variants located in a hotspot and/or critical domain without
benign variation (PM1). It is well established that missense
variants in MYH7 are the predominant class of pathogenic
alleles. The ExAC database (http://exac.broadinstitute.org/22)
provides a metric to express the deviation of variant counts
from the expected number (constraint score). Positive scores
indicate intolerance to variation, which is the case for MYH7
(z = 6.54). However, recent studies suggest that this is driven
by statistically significant clustering of pathogenic variants in
the head region (Po 3 × 10− 15, amino acids 181–937,
NM_000257).23,24 The CMP-EP concluded that this evidence
was most appropriately weighted as moderate through
application of the critical domain rule (PM1). PP2 was deemed
no longer applicable because it does not apply to variants
outside the head domain and to avoid double counting the
same evidence twice for variants in the head domain.
Other modifications
Rules deemed not applicable
Four rules of the pathogenic framework (PVS1, PM3, PP2,
PP4) and three rules of the benign framework (BS2, BP1, BP3)
were deemed not applicable either entirely or in the original
strength level suggested, and two additional rules were
removed for other reasons. Select rules are discussed here
and a full list of not applicable and removed rules, along with
a summary of the rationale, is provided in Supplementary
Text S2. PVS1 (null variant in a gene where loss of function
(LOF) is a known disease mechanism): MYH7 LOF variants
are very rare and their contribution to inherited
cardiomyopathy is incompletely understood. While there is
currently no evidence for a disease-causing role in the
heterozygous state, compound heterozygosity of LOF variants
along with missense variants can lead to extremely severe
presentations, mimicking recessive inheritance.25,26 The
CMP-EP assigned moderate weight to a LOF variant
(PVS1_Moderate, Table 1), which yields a classification of
variant of uncertain significance in the absence of case-level
data supporting pathogenicity. PM3 (variant detected in trans
with a pathogenic variant): While compound heterozygosity
leading to a more severe phenotype has been documented,
this rule was designed for traditional recessive inheritance.
Removed rules
PP5/BP6 (reputable source reports variant as pathogenic/
benign, but evidence is not accessible): The CMP-EP decided
expert curations should only be used if accompanied by the
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evidence used. Platforms such as ClinVar enable laboratories
to share the evidence on which an interpretation is based, and
the CMP-EP encourages this practice.
Performance of the new MYH7-specific rules
Sixty pilot variants were selected to cover a broad spectrum of
scenarios, while focusing on the types of data most commonly
encountered (Supplementary Figure S1, Supplementary
Table S4). The majority of the rules were applied at least
once (Supplementary Figure S2). The rules supporting
benign evidence were used the least, reflecting the
intentional bias toward the pathogenic spectrum. After
application of the modified ACMG/AMP framework by two
independent expert reviewers, 8/60 variants were discordantly
classified. Factors underlying discordance revealed two causes:
(i) 4 data errors (differences in the data used, such as arriving
at different proband or segregation counts), and (ii) 4 rule
applications that deviated from the intended use
(Supplementary Figure S3). After correcting for data
errors, concordance was 93%. Rules requiring a high level of
expert knowledge were more vulnerable to error (e.g., those
relying on segregation counts), exposing a significant
overhead associated with training curators. All discrepancies
were resolved upon review by the task team and did not
require full CMP-EP review. This represents a significant
improvement compared with the initial 10 variant pilot. The
pilot variants (31 associated with HCM and 6 with DCM)
have been submitted to ClinVar with a 3-star (expert panel–
approved) label. ClinVar IDs are listed in Supplementary
Table S4.
Laboratory internal data has a high impact and shows a
critical need to enable sharing of case-level information
When available, the CMP-EP also reviewed internal labora-
tory data from several of its members that was unpublished at
the time of curation (see Materials and Methods). For 25 pilot
variants, this impacted the application or strength for at least
one of the multiple proband, segregation, or de novo rules and
impacted the final classification of 12 variants (48%). Seven
variants were upgraded from likely pathogenic to pathogenic,
and another five increased from uncertain significance to
likely pathogenic (Figure 3, Supplementary Table S5). This is
a powerful demonstration of the impact of historically
decentralized, private data and illustrates an urgent need to
incentivize data sharing as well as to establish infrastructure
and standards to share and aggregate such case-level data.
Clinical judgment
Although the ACMG/AMP framework represents a major
step forward in our ability to classify variants in the context of
Mendelian disease, it will need continued improvement and
refinement as our understanding of these diseases develops. It
is premature to expect that even this improved, rule-based
framework will function without additional clinical judgment,
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which is a hallmark of medical practice. Clinical judgment
represents the capability of experts to consider additional, as
of yet unquantified factors, and adjust the weighting of
specific evidence elements intuitively based on deep experi-
ence and exposure to many cases over time. Prior studies have
begun to quantitate this phenomenon in the context of variant
classification.7 In our pilot, judgment led to overriding the
classification for two MYH7 variants where the CMP-EP
upgraded the rule-based classification of variant of uncertain
significance to likely pathogenic: p.Arg1420Trp (PM2, absent/
rare in controls; PS4_Moderate, present in 11 probands; PP3,
computational predictions favor pathogenic) and p.Arg1909-
Pro (PM2, absent/rare in controls; PM6, de novo occurrence
without confirmed paternity; PP3, computational predictions
favor pathogenic). Considering the extremely conservative
approaches used for several rules, the CMP-EP felt that the
evidence for both variants was sufficiently borderline (just one
additional supporting rule required to meet the criteria for
likely pathogenic) and the available evidence provided
additional specificity not accounted for by the rules to
warrant this upgrade (p.Arg1420Trp, additional probands not
counted due to conservative nature of the approach; p.
Arg1909Pro, phenotype included DCM and myopathy, and
additional segregations).
LIMITATIONS
Proband cohorts used to derive data on multiple occurrences
of variants largely represent diagnostic cases from broad
referral populations where clinical diagnoses were based on
information provided by ordering health-care providers.
Allele frequency thresholds were developed assuming auto-
somal dominant inheritance and were deliberately designed as
overly stringent to minimize the risk for false-positive interpreta-
tions, which can cause harm to the patients and their families.
In accordance with the ACMG/AMP parent framework,
these rules assume a single-variant disease paradigm.
CONCLUSIONS AND FUTURE DIRECTIONS
The CMP-EP created adjusted ACMG/AMP variant classifi-
cation rules that can be used for all MYH7-associated
cardiomyopathies. It is expected that our framework will
undergo iterative refinements catalyzed by its use, as well as
continuous improvements made to the parent framework by
the community, and the CMP-EP will provide updated
versions as needed. Future work will extend the MYH7
framework to other cardiomyopathy genes, which will likely
require only minimal additional specifications.
Finally, the CMP-EP will establish a sustained curation
process to apply the MYH7 rules to all variants presently in
the public domain with the goal to submit 3-star (expert
panel–reviewed) variant classifications along with the asso-
ciated evidence into ClinVar.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim.
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